The Contrived Mutant p53 Oncogene – Beyond Loss of Functions

Kanaga Sabapathy1,2,3,4*

1Division of Cellular and Molecular Research, National Cancer Centre Singapore, Humphrey Oei Institute of Cancer Research, Singapore, 2Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore, 3Institute of Molecular and Cellular Biology, Singapore, 4Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Mutations in p53 are almost synonymous with cancer – be it susceptibility to the disease or response to treatment – and therefore, are a critical determinant of overall survival. As most of these mutations occur in the DNA-binding domain of p53, many of the clinical correlations with mutant p53 have been initially relegated to the loss of its transcription-dependent activities as a tumor suppressor. However, significant efforts over the last two decades have led to the vast knowledge on the potential functions of the mutated p53 protein, which have been attributed to the physical presence of the mutant protein rather than the loss of its wild-type (WT) functions. Beyond the inhibitory effects of mutant p53 on the remaining WT protein that leads to the dominant-negative effect in the heterozygous state, mutant p53’s presence has also been significantly attributed to novel gain-of-functions that lead to addiction of cancer cells to its presence for survival, as well as for their ability to invade and metastasize, elevating it to a contrived oncogene that drives the cancer cells forward. This review will summarize the functional consequences of the presence of mutant p53 protein on cellular and organismal physiology.

**Keywords:** dominant-negative effect, gain-of-functions, mutant p53-addiction, oncogene, p53, tumor-suppressor

**MUTANT p53**

p53, one of the earliest identified tumor suppressors, has been overwhelmingly confirmed to be the most mutated gene across all cancer types through the recent avalanche of cancer genome sequencing efforts (1). Mutations in p53 occur in about 90% of the cases in its central DNA-binding domain (DBD), thereby leading to loss of its transactivation properties that are often associated with its tumor-suppressor functions [reviewed in Ref. (2)]. During the course of the evolution of the transformed cell, mutant p53 derived from the mutated allele co-exists with the wild-type (WT) p53 from the other allele for varying time periods, till the WT allele is generally lost through loss-of-heterozygosity (LOH), resulting in the sole existence of only the mutant p53 (Figure 1). Like most of the tumor suppressors that have a direct impact on tumor growth upon their loss of function – thus qualifying them as tumor suppressors – mutations in p53 were also thought to lead to loss of most of its tumor-suppressor functions that regulate almost all aspects of cellular physiology. Interestingly, during the co-existence phase of both the WT and mutant p53 proteins, haploinsufficiency leads to propensity for increased tumor development, as has been demonstrated in Li–Fraumeni patients
as well as in a large number of model organisms expressing the mutant p53 allele (3, 4). However, in contrast to most tumor suppressors, mutant p53 is unique in the sense that it has not only lost its tumor-suppressor functions, but evidence accumulating over the last two decades has assigned a wide variety of advantages to the cancer cell of having the mutant p53 protein. In short, the advantages of having a mutant p53 to the growth and survival of the tumor cells can be classified as a mirror image of the tumor-suppressor functions of WT p53 (Figure 2). Of interest is the fact that no other tumor suppressor has acquired such a wide array of novel functions as p53 when mutated, thereby elevating p53 to the status of a “contrived” oncogene, entirely on the basis that its functions as a tumor suppressor are turned on its head when the gene gets mutated. In this review, I will discuss the novel and acquired functions of mutant p53, specifically focusing on the DBD mutations.

**DOMINANT-NEGATIVE FUNCTIONS OF MUTANT p53 – AT THE EARLY STAGES**

Generally, in the early phases of cancer development, mutated p53 co-exists with the WT allele until the latter is lost due to LOH. In this co-existence phase, haploinsufficiency is a generally observed phenomenon associated with tumor development (5). However, effects of the mutant p53 over the WT’s regular functions – in a dominant-negative (DN) manner – have also been noted. Several early studies indirectly illustrated this DN effect, especially through the overexpression of the mutant p53 in WT p53 expressing cells, or vice versa. However, direct evidence for the DN effect of the mutant p53 protein on the WT p53 was shown in co-overexpression studies, demonstrating the quenching of WT p53’s ability to affect cellular transformation and transactivation of target genes, especially in transformed cell lines (6,
Co-expression of WT p53 with mutant p53 was also shown to affect the conformation of the former into a mutant conformation due to co-translation with the mutant form (8). Moreover, WT p53 was suggested to be inactivated through oligomerization with mutant p53 (9), and by inhibition of WT p53’s ability to bind to target gene promoters in a specific manner (6, 10). Concomitant to the effects on target gene activation, DN effects were noted on WT p53’s ability to induce cell death (11) and ras-induced senescence (12). Consequently, large efforts to analyze the DN effects of tumor-derived p53 mutants on the activation of several target genes have been undertaken in a systematic way using the yeast model, which was able to classify mutations as either dominant or recessive (13), and has also led to the cataloging of p53 mutations based on the ability to regulate a large number of p53-target genes (14).

Although the DN phenomenon has been well demonstrated in a large series of studies, the question that remained was its relevance when mutant p53 is expressed from its endogenous locus. This was resolved with the generation of the p53 mutant knock-in mouse models, whereby several groups confirmed the DN effects using p53mutant/+ mice in various primary cell types, including thymocytes, splenocytes, and embryonic stem cells, by comparing it with the p53−/− cohorts (15–18). Interestingly, while the DN effects were seen in some tissues, both on target gene activation and on cell survival, this was not the case in other cell types, as in primary fibroblasts in their growth, suggesting that the DN effect might be cell type, and possible stimulus dependent (18).

An interesting observation that emerges from all these studies with primary and transformed cells is that the DN effects on target gene activation and cell death are generally seen when cells are exposed to stress stimuli, including exposure to DNA-damaging agents, when p53 is activated and stabilized (15, 16, 18). By contrast, DN effect is not normally observed at baseline conditions, as there were no growth advantages to primary cells from p53mutant/+ mice, or with respect to spontaneous tumor development, both of which mirrors the p53−/− cells and mice (18, 19). Furthermore, although the DN effect can lead to almost complete ablation of target gene activation when observed, all p53mutant/+ mice generated so far have not been able to rescue the embryonic lethality due to the absence of Mdm2 (15, 18). Thus, these data collectively surmise that the DN effect of mutant p53 is exhibited when the levels of the mutant p53 is elevated in acute stress conditions, and thus, may have a significant consequence when patients are treated with chemotherapy and radiotherapy.

In this respect, early reports have suggested that at least three molecules of mutant p53 are required to impose a DN effect on one molecule of WT p53 (7, 20). Interestingly, although mutant
p53 protein has been shown to have a much longer-half life than WT p53, especially in tumor cell lines and in transfection studies, primary cells and tissues from p53mutant/+ mice do not exhibit elevated steady-state levels of the mutant p53 protein (18, 19). However, mutant p53 appears to be more abundant in tumor tissues from these mice, further alluding to the requirement of stress and/or oncogenic signals for mutant p53 stabilization (18, 19). Given that stress signals are also able to further stabilize mutant p53, it is not unexpected that the ratio of mutant p53 to WT is significantly high, thereby leading to the observed DN effects. In supporting this theory, reduction of the endogenous mutant p53 levels – using an hypomorphic mutant p53 knock-in mouse model – was indeed shown to alleviate the DN effects, both on target gene activation and cell death upon irradiation (18). Similarly, reduction of the WT p53 levels in a p53mutant/+ mouse strain also led to exhibition of the DN effect in tumors (21). Thus, these observations consolidate the case for the requirement of a significant increase in mutant p53 levels – as seen in tumor cells, or in primary cells upon exposure to stress stimuli – for the manifestation of the DN effects, which could be ameliorated by reducing the mutant protein levels. This implies that in a clinical setting, strategies that would reduce mutant p53 protein levels without an effect on WT p53 during therapy would lead to better efficacy of treatment and would be a future prospect that should be followed up.

Mechanistically, there are a few modes of operation of the DN effect. The mutant p53, which itself is unable to specifically bind to the p53-response elements, binds to the WT p53, thereby quenching it away from target gene promoters (6, 10). Alternatively, mutant p53 quenches away co-factors that are required for transactivation by the WT p53 bound to the promoter, thereby reducing the potency of the WT protein (22). In addition, mutant p53 has been suggested to form aggregates, akin to those seen in protein misfolding diseases. Herein, it has been suggested that the WT p53 protein is engulfed into mutant p53 fibrillar and granular aggregates, whereby the misfolded mutant protein sequesters the WT form, thus leading to inactivation of the WT function (23). Whatever the mechanism may be, the underlying concept is that the ability of mutant p53 to bind to wild-p53 when in excess is causal to the DN effect, which could thus offer an avenue for exploitation for therapeutic benefit. While there are currently no known ways of overcoming the DN effect, potential strategies that lead to the degradation of mutant p53 specifically without affecting the WT protein will be the way forward in ameliorating the DN effect.

**AFTER LOH – THE MUTANT p53-ADDICTON PHENOMENON**

While the phenomenon of addiction to oncogenes has been well established (24), mutated tumor suppressors have never been earlier reported to provide a survival advantage to tumor cells due to any novel acquired functions. However, two reports in the mid-2000s showed for the first time that silencing the expression of endogenous mutant p53 can lead to increased apoptosis (25), and reduced tumor growth in vivo (26), formally demonstrating the phenomenon of addiction of tumor cells to mutant p53’s presence. In addition, indirect evidence for the requirement for mutant p53 for survival of cells in a phospholipase D-dependent manner was also noted (27). This phenomenon is now well established in a large number of subsequent studies. However, the causal mechanisms are still relatively elusive. In earlier studies, a role for transactivation by mutant p53 of cell growth regulation genes was suggested, as the transactivation deficient DBD p53 mutants were unable to provide a growth advantage (28). In the other studies, mutant p53-mediated suppression of canonical p53-target genes was suggested to be the mechanism, which wasameliorated upon the silencing of mutant p53 expression, leading to cell death. In this latter case, hypomethylation appeared to be involved, as trichostatin A – a HDAC inhibitor – was found to relief the mutant p53-dependent suppression (25). Other recent studies have confirmed this possibility, using other HDAC inhibitors, such as SAHA (29) and sodium butyrate (30).

Recent in vivo work in mice has also confirmed that destabilization of mutant p53 expression leads to apoptosis and reduction of tumor growth (31). In this case, mutant p53 was destabilized through the inhibition of the HSF90/HDAC6 chaperone machinery that is often upregulated in cancers, collectively highlighting the mutant p53-addiction phenomenon, and that degradation of mutant p53 can indeed enhance tumor cell death and improve therapy. While addiction to mutant p53 appears to be critical for the survival of the cancer cell, the exact point at which they get addicted to mutant p53 is not understood. While the transformed cells could be expected to become addicted to the presence of mutant p53 at the point in time of loss of the remaining WT p53 allele, it is likely that further events are required for this phenomenon to occur. Moreover, whether addiction to mutant p53 is a universal phenomenon in all cell types also requires further systematic analyses.

**ROLE REVERSAL FROM TUMOR SUPPRESSOR TO ONCOGENE: GAIN OF NOVEL FUNCTIONS**

Similar to mutant p53 addiction, the direct advantages conferred by the presence of the mutant p53 protein have been understood primarily through cell culture studies where isogenic cell lines without p53 expression have been used to analyze the effects of the overexpressed mutant p53. These have resulted in the uncovering of a plethora of gain-of-function (GOF) effects, almost all of which provide survival/growth advantage to the cell. First direct evidence came from the overexpression of several human (e.g., R175H, R248W, R273H, and R281G) and mouse mutants in p53 null cell lines that lead to increased cellular growth in soft agar and increased tumorigenicity in immunocompromised mice (32). While this was the first case of evaluating the effects of the mutant version of the natural tumor suppressor, earlier studies using a mutant p53 – at that time thought to be the natural existing form prior to the knowledge that p53 is actually a tumor suppressor – also showed growth advantage due to its overexpression (33). In addition, there are multiple other parameters associated with genomic instability that were noted due to the
overexpression of mutant p53, including gene and centrosome amplification and disruption of spindle checkpoint (34–37). Consistently, overexpression of mutant p53 also led to resistance to death induced by a variety of chemotherapeutic drugs and DNA-damaging agents (38–41), as well as by anoikis (42). More recently, expression of mutant p53 was also shown to enhance the Warburg effect on cancer cells, promoting GLUT1 translocation to the plasma membrane, and thus enhancing glucose uptake (43).

Not unexpectedly, many studies have also evaluated if the expression of mutant p53 would enhance cellular invasion and migration and found that to be the case in a variety of 2D and 3D cellular systems (18, 44–46). Furthermore, a role for mutant p53 in promoting cellular reprogramming was also demonstrated (47), suggesting that mutant p53’s presence would lead to the survival and replenishment of the potential cancer stem cells, leading to their ability to colonize the adjacent territory.

At the organismal level where mutant p53 is expressed from its own locus – reflecting the status in human cancer conditions – GOF properties were also noted with the generation of the p53 mutant knock-in mice. The initial data demonstrated that the p53R172H mice (equivalent to human R175H) were more tumor prone with more carcinomas – reflecting a change in tumor spectrum. They also had increased metastasis compared to the p53 null mice, in the absence of Mdm2, which leads to increased mutant p53 levels (15, 16). Further studies have cemented these findings, where the presence of the R172H mutant p53 protein conferred significant growth and metastatic propensity to tumors compared to the loss of p53, in several oncogene-induced models, including Ras and APC, in a variety of tumor types such as lung and pancreatic ductal adenocarcinomas (46, 48, 49). Similar observations were also noted with other mutations, such as the R270H and R273H in breast and lung cancer models (50, 51). These data mooted the idea that all mutant p53 would have GOF properties, and that this may depend on the stabilization of the mutant p53 in the cancer cell context, as normal untransformed tissues from the mutant p53 bearing mice did not have significant growth advantage and did not display increased steady-state levels of the mutant protein (19). However, this theory came under challenge through the analyses of another hot-spot p53 mutant knock-in mouse strain (the R246S, equivalent to human R249S). In this case, the R246S mutant mice did not display any tumor latency difference or metastatic advantage even in the absence of Mdm2 (18). Similar results were also seen with other hot-spot mutant knock-in mice strains, in which the R248Q had a strong GOF phenotype in contrast to the G245S mutant (52), collectively alluding the fact that GOF may not be a universal phenomenon, and that elevation of mutant p53 levels may not be sufficient for their exhibition.

Nonetheless, as observed in the cell culture-based studies, there was a propensity to have more hematopoietic or mesenchymal stem cells in the R248Q mutant p53 knock-in mice, indicative of an effect of mutant p53 on the plasticity of the stem cell population (52). Besides the effects on tumor metastasis and aggressiveness, the effects of mutant p53 on several other aspects of physiology have been noted using the knock-in mice strains. For instance, there was increased inflammation and tissue damage, primarily due to upregulation of inflammatory cytokines that were induced by mutant p53-mediated prolonged activation of NFKB signaling (53). Angiogenesis was also shown to be enhanced due to mutant p53 expression, through the activation of ID4 expression in cell culture studies (54). These studies collectively indicate that expression of mutant p53 in tumor cells, as seen in the case with human cancers, as well as in normal tissues as analyzed from animal studies, has far-reaching consequences on organismal physiology.

While enormous amounts of data from cellular systems and animal models highlight the existence of GOFs of mutant p53, albeit to varying degrees perhaps depending on several contextual factors, the main question is the relevance of this phenomenon in humans. A noteworthy point is that humans generally do not carry a mutant p53 allele in non-transformed tissues, except in the case of the Li–Fraumeni patients. Thus, the GOF properties would be of relevance in the large majority of tumors that eventually retain only the mutant allele. On the other hand, the Li–Fraumeni patients would be expected to have one allele that is WT in all untransformed tissues, except in cases where LOH would result in or occur with other transforming events that lead to tumorigenesis. In this context, transcriptomic analyses of p53+/− vs. p53mutant/mutant primary tissues (e.g., thymus) from the knock-in mice remarkably did not reveal any significant changes (18), highlighting that GOF is generally not observed in untransformed cellular contexts. Thus, even in the Li–Fraumeni group, the GOFs and addiction to mutant p53 would be a phenomenon that would be of relevance primarily in the cancer cell context. This has been exemplified in a large number of studies that have evaluated the role of mutant p53 in response to chemotherapy, which have generally shown poor prognosis associated with the presence of mutant p53 (55). This, however, could either be due to the DN effect or the GOF functions, as many of these reports have not teased out the status of the other allele in the patient samples. Thus, the presence of mutant p53 in human tumors does indeed exert a negative effect in response to therapy, warranting in-depth investigations into the mechanisms of actions of mutant p53.

**MECHANISMS AND MEDIATORS OF MUTANT p53 GAIN-OF-FUNCTIONS**

Since the demonstration of GOF of mutant p53, extensive efforts have gone on to examine the mechanistic basis of this phenomenon [reviewed in Ref. (56)]. At least four inter-related categories of actions have emerged: novel target gene activation through direct DNA binding; enhancement of target gene activation due to co-factor binding to mutant p53; co-operation with other transcription factors to activate other transcriptomes; and binding to factors that indirectly result in activation of other pathways.

In the first instance, while DBD-mutant p53 has lost its abilities to bind to canonical p53-responsive elements on target gene promoters, several studies have alluded to the ability of mutant p53 to bind to novel target gene promoters to activate them. It has been proposed that mutant p53 interacts with matrix-attachment regions (MARs), thereby recognizing structures rather than
sequences (57). This results in the activation or repression of mutant p53-target genes, the list of which has been steadily growing. In brief, the targets can be categorized into either genes that are upregulated or down-regulated by the presence of mutant p53, including both coding and non-coding genes involved in promoting proliferation, inhibiting cell death, promoting migration, and inflammation. In the former category exists a large array of genes, including growth factors/receptors, such as bFGf, Egfr, Igf1, Igf1r, Il6, and TNF; cell death/survival genes, such as bcl-xl, procaspase 3; oncogenes and transcription factors, such as c-fos; c-Myc, Egfr1, NkRb, Ras, and Egri; metastasis regulators, such as twist-1; microRNAs, such as mir 155 and mir128-2; and many others [reviewed in Ref. (2)]. The second category of suppressed genes includes Fas, Mst-1/msp, mir130b, mir27a, mir223, and a large also a array of the canonical p53-target genes that appear to be suppressed by the presence of mutant p53 (25).

Next, regulation of target genes by mutant p53 can be facilitated by co-operative binding and post-translational modifications of the mutant p53 protein. For instance, mutant p53’s activity has been shown to be enhanced by binding with PML and Pin1 (58, 59). In addition, mutant p53 has also been shown to co-operate with other transcription factors, such as NF-Y, VDR, Sp1, and SREBP, to enhance the activation of their target genes (60–63). Conversely, mutant p53 has also been shown to bind to p63 and p73 to inhibit the activation of the latter groups’ targets (64). Finally, an indirect role for mutant p53 in activation of various pathways has emerged. For example, mutant p53 has been shown to bind to p63 and p73 to inhibit the activation of the latter groups’ targets (64).

The diversity in mechanisms and mediators of mutant p53’s GOF function allude to the fact that these may be dependent and vary according to the cell type, the mutation type or the stimuli. Furthermore, GOFs would also likely be temporally dictated during the evolution of the transformed cell. Hence, efforts aimed at targeting mutant p53 would have to take into account these factors that have to be elucidated and characterized.

**FUTURE OF MUTANT p53**

One can envisage that all the years of work on mutant p53 and its functions will now put the research community in good stead in trying to target its functions for clinical benefit, and the current status of these efforts is reviewed in the adjoining chapters. Nonetheless, important considerations have yet to be worked out. These include several questions, such as how can the DN effect be mitigated when treating patients whose tumors retain the WT allele; what is the effect of the DN phenomenon in the daily lives of LF patients, especially when they are exposed to a variety of signals that may have an acute effect on p53 activation; precisely when and where is GOF manifested and addiction to mutant p53 occur; and what is the trigger point for GOF of mutant p53. Thus, while general targeting strategies are being worked out, more work is required to realize the dream of targeting all types of mutant p53 that are different, and thus, likely require specific molecules/dugs to counter them.

**AUTHOR CONTRIBUTIONS**

KS planned and wrote the manuscript.

**ACKNOWLEDGMENTS**

We thank the National Medical Research Council of Singapore for funding KS’ research on p53.

**REFERENCES**

1. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature (2014) **23**:495–501. doi:10.1038/nature12912

2. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev (2012) **15**:1268–86. doi:10.1101/gad.190678.112

3. Donohoe LA. Insights into wild-type and mutant p53 functions provided by genetically engineered mice. Hum Mutat (2014) **35**:715–27. doi:10.1002/humu.22507

4. Merino D, Malkin D. p53 and hereditary cancer. Subcell Biochem (2014) **85**:1–16. doi:10.1007/978-94-017-9211-0_1

5. Payne SR, Kemp CJ. Tumor suppressor genetics. Carcinogenesis (2005) **26**:2031–45. doi:10.1093/carcin/bgi223

6. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibits p53-regulated gene expression. Science (1993) **265**:827–30.

7. Sun Y, Dong Z, Nakamura K, Collburn NH. Dosage-dependent dominance over wild-type p53 of a mutant p53 isolated from nasopharyngeal carcinoma. FASEB J (1993) **7**:944–50.

8. Milner J, Medcalf EA. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell (1991) **65**:765–74.

9. Kraiss S, Quaiser A, Oren M, Montenarh M. Oligomerization of oncoprotein p53. J Virol (1988) **62**:4737–44.

10. Shawlain E, Zauberman A, Ginsberg D, Oren M. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol (1992) **12**:5581–92.

11. Gottlieb E, Haffner R, von Rüden T, Wagner EF, Oren M. Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. EMBO J (1994) **15**:1368–74.

12. Berrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell (1997) **88**:593–602.

13. Ing a A, Cresta S, Monti P, Aprile A, Scott G, Abbondandolo A, et al. Simple identification of dominant p53 mutants by a yeast functional assay. Carcinogenesis (1997) **18**:2019–21.

14. Dearth LR, Qian H, Wang T, Baroni TE, Zeng J, Chen SW, et al. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis (2007) **28**:289–98. doi:10.1093/carcin/bgl132

15. Lang GA, Iwakuma T, Suh YH, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) **17**:861–72. doi:10.1016/j.cell.2004.11.006

16. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) **119**:487–60. doi:10.1016/j.cell.2004.11.004

17. Lee MK, Sabapathy K. The R246S hot-spot p53 mutant exerts dominant-neg-ative effects in embryonic stem cells in vitro and in vivo. J Cell Sci (2008) **121**:1899–906. doi:10.1242/jcs.022822
18. Lee MK, Teoh WW, Phang BH, Tong WM, Wang QZ, Sabapathy K. Cell-type, dose, and mutation-type specificity dictates mutant p53 functions in vivo. *Cancer Cell* (2012) 25:51–64. doi:10.1016/j.ccc.2012.10.022

19. Terzian T, Suh YA, Ikawakuma T, Post SM, Neumann M, Lang GA, et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. *Genes Dev* (2008) 15:1337–44. doi:10.1101/gad.1662908

20. Chan WM, Szu WY, Lau A, Poon RY. How many mutant p53 molecules are needed to inactivate a tetramer? *Mol Cell Biol* (2004) 24:3536–51. doi:10.1128/MCB.24.8.3536-3551.2004

21. Wang Y, Suh YA, Fuller MY, Jackson JG, Xiong S, Terzian T, et al. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. *J Clin Invest* (2011) 121:893–904. doi:10.1172/JCI44504

22. Blagodatsky MV, p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect. *FASEB J* (2000) 14:1901–7. doi:10.1096/fj.99-1078rev

23. Silva JL, Rangel LP, Costa DC, Cordeiro Y, De Moura Gallo CV. Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor. *Biosci Rep* (2013) 33:593–603. doi:10.1042/BSR20130065

24. Weinstein IB, Joe A. Oncogene addiction. *Cancer Res* (2008) 68:3077–80. doi:10.1158/0008-5472.CAN-07-3293

25. Vikhanskaia F, Joe MK, Mazzeotti M, Broggiini M, Sabapathy K. Cancer-derived p53 mutants suppress p53-target gene expression – potential mechanism for gain of function of mutant p53. *Nucleic Acids Res* (2007) 35:2093–104. doi:10.1093/nar/gkm099

26. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. Mutant p53 gain of function mutations in p53. *Nat Rev Cancer* (2009) 9:593–603. doi:10.1038/nrc2580

27. Li D, Marchenko ND, Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. *Cell Death Differ* (2011) 18:1904–13. doi:10.1038/sj.cdd.4402076

28. Hui L, Zheng Y, Yan Y, Bargonetti J, Foster DA. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. *Oncogene* (2006) 25:7305–10. doi:10.1038/sj.onc.1209973

29. Scian MJ, Stagliano KE, Ellis MA, Hassan S, Bowman M, Miles MF, et al. Modulation of gene expression by tumor-derived p53 mutants. *Cancer Res* (2004) 64:7447–54. doi:10.1158/0008-5472.CAN-04-1568

30. Li D, Marchenko ND, Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. *Cell Death Differ* (2011) 18:1904–13. doi:10.1038/sj.cdd.4402076

31. Yan W, Liu S, Xu E, Zhang J, Zhang Y, Chen X, et al. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. *Oncogene* (2006) 25:559–69. doi:10.1038/sj.onc.1209572

32. Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, et al. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. *Nature* (2015) 523:352–6. doi:10.1038/nature14430

33. Dittmer D, Piti S, Zambetti G, Chu S, Teresky AK, Moore M, et al. Gain of function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. *Am J Pathol* (1994) 145:702–14.

34. Adorno M, Cordononsi M, Montagner M, Dupont S, Wong C, Hann B, et al. A mutant p53/Smad complex opposes p63 to empower TGFβ-induced metastasis. *Cell* (2009) 137:87–98. doi:10.1016/j.cell.2009.01.039

35. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Kariim S, et al. Mutant p53 drives invasion by promoting integrin recycling. *Cell* (2009) 139:1327–41. doi:10.1016/j.cell.2009.11.026

36. Sarig R, Rivlin N, Brosh R, Bornstein C, Kamer I, Ezra O, et al. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. *J Exp Med* (2010) 207:2127–40. doi:10.1084/jem.20100797

37. Caulin C, Nguyen T, Lang GA, Goepfert TM, Brinkley BR, Cai WW, et al. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. *J Clin Invest* (2007) 117:893–901. doi:10.1172/JCI31721

38. Morten J, Timpson P, Karim SA, Bidgway RA, Athineos D, Doyle B, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. *Proc Natl Acad Sci U S A* (2010) 107:246–51. doi:10.1073/pnas.0908428107

39. Heinlein C, Krepulat F, Löhr J, Speidel D, Depwert P, Tolstonog GV. Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis. *Int J Cancer* (2008) 122:1701–9. doi:10.1002/ijc.23317

40. Duan W, Gao L, Wu X, Hade EM, Gao JX, Ding H, et al. Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumour formation in transgenic mice. *PLoS One* (2009) 4:e5563. doi:10.1371/journal.pone.0005563

41. Harel W, Marchenko N, Xu S, Yu SX, Weng W, Moll U. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. *Cell Death Differ* (2013) 20:898–909. doi:10.1038/cdd.2013.17

42. Cooks T, Pateras IS, Tarico O, Solomon H, Schetter AJ, Wilder S, et al. Mutant p53 prolongs NF-kb activation and promotes chronic inflammation and inflammation-associated colorectal cancer. *Cancer Cell* (2013) 13:634–46. doi:10.1016/j.ccc.2013.03.022

43. Fontemaggi G, Dell’Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, et al. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. *Nat Struct Mol Biol* (2009) 16:1086–93. doi:10.1038/nsmb.1669

44. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs. *Clin Cancer Res* (2005) 137A:4384–56. doi:10.1097/01.AJR.0000123565.01211.00

45. Berkouk K, Carter C, Auffray C, Al-Shehhi H, Zand R, Kagan S, et al. Promyelocytic leukemia protein is required for gain of function by mutant p53. *Cancer Res* (2009) 69:4818–26. doi:10.1158/0008-5472.CAN-08-4010

46. MEF ras-transformants–expressing gain of function MTp53. *Oncogene* (2003) 22:2960–6. doi:10.1038/sj.onc.1206405

47. Scian MJ, Stagliano KE, Anderson MA, Hassan S, Bowman M, Miles MF, et al. Tumor-derived mutant p53 induces NF-kB gene expression. *Mol Cell Biol* (2005) 25:10097–110. doi:10.1128/MCB.25.22.10097-10110.2005

48. Vikhanskaia F, Sididiq MM, Kei Lee M, Broggiini M, Sabapathy K. Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs. *Clin Cancer Res* (2005) 11:4384–56. doi:10.1097/01.AJR.0000123565.01211.00
59. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell (2011) 20:79–91. doi:10.1016/j.ccr.2011.06.004

60. Chicas A, Molina P, Bargonetti J. Mutant p53 forms a complex with Sp1 on HIV-LTR DNA. Biochem Biophys Res Commun (2000) 279:383–90. doi:10.1006/bbrc.2000.3965

61. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, et al. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell (2006) 10:191–202. doi:10.1016/j.ccr.2006.08.013

62. Stambolsky P, Tabach Y, Fontemaggi G, Wess L, Maor-Aloni R, Siegfried Z, et al. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell (2010) 17:273–85. doi:10.1016/j.ccr.2009.11.025

63. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 148:244–58. doi:10.1016/j.cell.2011.12.017

64. Li Y, Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene (2007) 26:2220–5. doi:10.1038/sj.onc.1210311

65. Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol (2007) 9:573–80. doi:10.1038/ncb1571

Conflict of Interest Statement: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 Sabapathy. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.